CRYSTAL trial of stiripentol in primary hyperoxaluria

Phase 3, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) and primary hyperoxaluria type 3 (PH3) comparing Diacomit with Matched placebo (2 arms). Primary endpoint: Percent change in 24-hour urinary oxalate excretion corrected for body surface area from baseline to Month 6. Planned start Jul 2026; status: authorised.